Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

Type 1 Diabetes Clinical Trial

Official title:

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01954459
• Other study ID #: 1306012208
• Secondary ID: R01DK085618-01
• Status: Terminated
• Phase: Early Phase 1
• Start date: September 2013
• Est. completion date: June 2016

Study information

• Verified date: March 2020
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will investigate the effect of wearing a small warming patch, the InsuPatch, at the site of the continuous glucose monitor (CGM), also called a sensor. Specifically, we will be looking to see if using the InsuPatch (IP) improves the accuracy of the continuous glucose monitor.

Description:

Hypotheses:

1. Warming of the skin and subcutaneous tissue with the InsuPatch device will improve the accuracy of a CGM as compared to a CGM used alone when both are calibrated with a standard laboratory quality glucose measuring reference standard.

2. Warming of the skin and subcutaneous tissue with the InsuPatch device will reduce the lag time of the CGM, as compared to a CGM used alone when both are calibrated with a standard laboratory quality glucose measuring reference standard.

3. The combination of the InsuPatch device and a CGM will be well-tolerated and not cause skin irritation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 44 Years

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least 12 months.

2. Age 8 years to less than 45 years old.

3. Subject understands the study protocol and agree to comply with it.

4. Subject is on insulin pump or injection-based basal-bolus therapy

5. Subject comprehends written English.

6. For females, subject not intending to become pregnant during the study.

7. Informed Consent Form signed by the subject

8. No history of altered skin integrity, poor wound healing, adhesive allergy, or previous infection from sensor wear.

9. Hemoglobin A1C =10%

Exclusion Criteria:

1. The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol

2. The presence of any of the following diseases:

a. Current use of systemic corticosteroids (within the last week) b. Other major illness that in the judgment of the investigator might interfere with the completion of the protocol i. Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment

3. Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)

4. Current or past use of a continuous glucose sensor is not an exclusion criterion.

5. Active skin condition that would affect sensor placement

6. Use of acetaminophen or Vitamin C supplement within the last 7 days

7. Subject is deemed by the Investigator to be unwilling or unable to follow the protocol;

8. Pregnancy A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study.

-

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Device:
• Insupatch
Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
• Continuous glucose sensor
Glucose sensor inserted without warming patch

Locations

Country	Name	City	State
United States	Yale University School of Medicine	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.	Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use, comparing sensor glucose readings and signal data to serum Yellow Springs Instrument (YSI) glucose measurements, with each subject acting as his or her own control.	4 hours after lunch, 8 hours after breakfast